



Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System

October 19, 2007

Stereotaxis to Demonstrate Advanced Coronary & Peripheral Navigation,
CTO Vessel Road Mapping at TCT 2007

Stereotaxis' Mobile Vascular Showroom at Booth 8093

ST. LOUIS, Oct. 19 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it will be showcasing the interventional cardiology capabilities of its Niobe(R) Magnetic Navigation System at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington D.C., October 20 to 25, 2007. Demonstrations in Stereotaxis' Mobile Vascular Lab, the presentation of new clinical data and a live case presentation will underscore the simplicity, safety and precision that Stereotaxis can bring to a variety of vascular interventions.

The Stereotaxis system utilizes advanced, magnet-guided navigational technology designed to help interventional cardiologists perform interventional procedures with enhanced safety and precision. With systems installed at more than 70 leading hospitals worldwide, physicians have used the Stereotaxis system to perform over 2,000 percutaneous coronary interventions (PCI) and other guide wire-based vascular procedures, as well as more than 8,000 complex electrophysiology mapping and ablation procedures, on the left and right sides of the heart.

Clinical Presentations

Stereotaxis will host a breakfast symposium at TCT on Tuesday, October 23, 2007 at 7:00 a.m., in Room 144C, at which leading, distinguished interventional cardiologists will present their clinical experiences using the Niobe system for percutaneous coronary interventions as well as total occlusions and other peripheral applications.

Ferdinand Kiemeneij, M.D., Ph.D., from Onze Lieve Vrouwe Gasthuis (OLVG) in Amsterdam will present "Stereotaxis experience at OLVG: The First 500 Patients;" Robert Jan Van Geuns, M.D., Thoraxcenter at Erasmus Medical Center in Rotterdam, will present "Integration of MSCT Imaging in Coronary Magnetic Navigation: From Type A Lesions to Total Occlusions;" and John Young, M.D., Swedish Heart & Vascular Institute in Seattle will discuss "Emerging Peripheral Applications of the Stereotaxis System." The panel will be moderated by Patrick Serruys, M.D. of the Thoraxcenter at Erasmus Medical Center in Rotterdam.

Separately, New York Presbyterian Hospital / Columbia University Medical Center and Swedish Heart & Vascular Institute will present live cases using Stereotaxis technology to perform complex PCI procedures on Tuesday, October 23, in the Main Arena.

Cath Lab of the Future

Stereotaxis will demonstrate important advances in vascular interventional technology and outline plans to advance the therapeutic care of patients in the areas of CTO crossing using a steerable RF guidewire, as well as new approaches to the treatment of structural heart disease. The company will present this vision of the future at the "Cath Lab of the Future," which is sponsored by TCT and located in the center of the TCT exhibit hall, level two.

This will complement the Stereotaxis Mobile Vascular Lab on display in the Main Exhibit Hall.

The Stereotaxis Mobile Vascular Lab

Stereotaxis' Mobile Vascular Lab will be open for the duration of TCT in booth 8093. Company representatives will be on hand to demonstrate the Niobe system's advanced coronary and peripheral navigation capabilities. Powerful, easy-to-use technologies such as CTO vessel road mapping, image integration and global connectivity capabilities of Odyssey(TM) Network Solutions will also be showcased in the Mobile Vascular Lab.

The Transcatheter Cardiovascular Therapeutics symposium, sponsored by the Cardiovascular Research Foundation, will take place at the Washington Convention Center in Washington, DC from Saturday, October 20 through Thursday,

October 25, 2007.

To register for Stereotaxis' breakfast symposium, please contact Stereotaxis at 314-678-6169, as seating is limited.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ

materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.

-0-

10/19/2007

/CONTACT: company, Jim Stolze, Chief Financial Officer of Stereotaxis, Inc., +1-314-678-6105; or investors, Doug Sherk or Jenifer Kirtland, +1-415-896-6820, for Stereotaxis, Inc.; or media, Steve DiMattia of EVC Group, Inc., +1-646-201-5445, for Stereotaxis, Inc./
/Web site: <http://www.stereotaxis.com> /
(STXS)

CO: Stereotaxis, Inc.

ST: Missouri, District of Columbia

IN: HEA MTC

SU: TDS PDT

MX-JR

-- AQF013A --

1751 10/19/2007 06:30 EDT <http://www.prnewswire.com>